Switch theme
Sign up to access all valuation multiples
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.
1923
2.8K+
LTM Revenue $875M
LTM EBITDA $239M
$6.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Alk-Abello has a last 12-month revenue (LTM) of $875M and a last 12-month EBITDA of $239M.
In the most recent fiscal year, Alk-Abello achieved revenue of $834M and an EBITDA of $210M.
Alk-Abello expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Alk-Abello valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $875M | XXX | $834M | XXX | XXX | XXX |
| Gross Profit | $565M | XXX | $535M | XXX | XXX | XXX |
| Gross Margin | 65% | XXX | 64% | XXX | XXX | XXX |
| EBITDA | $239M | XXX | $210M | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 25% | XXX | XXX | XXX |
| EBIT | $193M | XXX | $164M | XXX | XXX | XXX |
| EBIT Margin | 22% | XXX | 20% | XXX | XXX | XXX |
| Net Profit | $145M | XXX | $123M | XXX | XXX | XXX |
| Net Margin | 17% | XXX | 15% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $40.2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Alk-Abello's stock price is DKK 178 (or $27).
Alk-Abello has current market cap of DKK 39.4B (or $5.9B), and EV of DKK 39.7B (or $6.0B).
See Alk-Abello trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6.0B | $5.9B | XXX | XXX | XXX | XXX | $0.66 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Alk-Abello has market cap of $5.9B and EV of $6.0B.
Alk-Abello's trades at 7.2x EV/Revenue multiple, and 28.5x EV/EBITDA.
Equity research analysts estimate Alk-Abello's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Alk-Abello has a P/E ratio of 41.0x.
See valuation multiples for Alk-Abello and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5.9B | XXX | $5.9B | XXX | XXX | XXX |
| EV (current) | $6.0B | XXX | $6.0B | XXX | XXX | XXX |
| EV/Revenue | 6.8x | XXX | 7.2x | XXX | XXX | XXX |
| EV/EBITDA | 25.0x | XXX | 28.5x | XXX | XXX | XXX |
| EV/EBIT | 30.9x | XXX | 36.4x | XXX | XXX | XXX |
| EV/Gross Profit | 10.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 41.0x | XXX | 48.3x | XXX | XXX | XXX |
| EV/FCF | 218.0x | XXX | -440.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAlk-Abello's last 12 month revenue growth is 12%
Alk-Abello's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Alk-Abello's rule of 40 is 31% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Alk-Abello's rule of X is 57% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Alk-Abello and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 25% | XXX | XXX | XXX |
| EBITDA Growth | 23% | XXX | 43% | XXX | XXX | XXX |
| Rule of 40 | 31% | XXX | 37% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 57% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 28% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 10% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 44% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Alk-Abello acquired XXX companies to date.
Last acquisition by Alk-Abello was XXXXXXXX, XXXXX XXXXX XXXXXX . Alk-Abello acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Alk-Abello founded? | Alk-Abello was founded in 1923. |
| Where is Alk-Abello headquartered? | Alk-Abello is headquartered in Denmark. |
| How many employees does Alk-Abello have? | As of today, Alk-Abello has 2.8K+ employees. |
| Who is the CEO of Alk-Abello? | Alk-Abello's CEO is Mr. Peter Halling. |
| Is Alk-Abello publicy listed? | Yes, Alk-Abello is a public company listed on CSE. |
| What is the stock symbol of Alk-Abello? | Alk-Abello trades under ALK B ticker. |
| When did Alk-Abello go public? | Alk-Abello went public in 2005. |
| Who are competitors of Alk-Abello? | Similar companies to Alk-Abello include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of Alk-Abello? | Alk-Abello's current market cap is $5.9B |
| What is the current revenue of Alk-Abello? | Alk-Abello's last 12 months revenue is $875M. |
| What is the current revenue growth of Alk-Abello? | Alk-Abello revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of Alk-Abello? | Current revenue multiple of Alk-Abello is 6.8x. |
| Is Alk-Abello profitable? | Yes, Alk-Abello is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Alk-Abello? | Alk-Abello's last 12 months EBITDA is $239M. |
| What is Alk-Abello's EBITDA margin? | Alk-Abello's last 12 months EBITDA margin is 27%. |
| What is the current EV/EBITDA multiple of Alk-Abello? | Current EBITDA multiple of Alk-Abello is 25.0x. |
| What is the current FCF of Alk-Abello? | Alk-Abello's last 12 months FCF is $27.4M. |
| What is Alk-Abello's FCF margin? | Alk-Abello's last 12 months FCF margin is 3%. |
| What is the current EV/FCF multiple of Alk-Abello? | Current FCF multiple of Alk-Abello is 218.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
